Skip To Main Content
Soria-Bretones I on Muck Rack

Soria-Bretones I

Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Soria-Bretones

Contact Soria-Bretones, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Protein arginine methyltransferase 5 (PRMT5) is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer

|
By Chang TC, Lee KM, Soria-Bretones I
| nlm.nih.gov
This is a preprint. It has not yet been peer reviewed by a journal. The National Library of Medicine is running a pilot to include preprints that result from research funded by NIH in PMC and PubMed. Res Sq. Display options Format doi: 10.21203/rs.3.rs-2966905/v1. Preprint PMID: 37502925 PMCID: PMC10371097 DOI: 10.21203/rs.3.rs-2966905/v1 Item in Clipboard Display options Abstract CDK4/6 inhibitors (CDK4/6i) have improved survival of patients with estrogen receptor-positive (ER+) breast cancer.
Open in Who Shared Issue with article?
See all 1 articles